Hosted on MSN

Disc Medicine stock slides after FDA fast-track approval doubts surface — Wall Street calls it an 'overreaction'

・Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule. ・Wall Street analysts dismissed the media ...